Moxalactam for treatment of pelvic infections after cesarean delivery.
Moxalactam was given to 136 women for treatment of uterine infections after cesarean delivery. After an intravenous loading dose of 2 g, 36 women received 3 g daily and 100 were given 6 g daily. The clinical success rates of these two regimens were 86% and 89%, respectively; however, in four of five women for whom treatment with the 3-g daily dose failed, extensive surgery was necessary for cure. A total of 395 pathogens was isolated from these women with polymicrobial infections, and almost 90% were susceptible to moxalactam at less than or equal to 32 micrograms/ml. Adverse effects of therapy were minimal. Thus, moxalactam given initially as a dosage of 6 g daily is effective for treatment of women with pelvic infections after cesarean delivery.
D000328:Adult; D002481:Cellulitis / Q000188:drug therapy; D002511:Cephalosporins / Q000627:therapeutic use*; D002513:Cephamycins / Q000009:adverse effects / Q000627:therapeutic use*; D002585:Cesarean Section; D005260:Female; D006801:Humans; D008826:Microbial Sensitivity Tests; D009070:Moxalactam; D011247:Pregnancy; D011645:Puerperal Infection / Q000188:drug therapy* / Q000382:microbiology
D002511:Cephalosporins; D002513:Cephamycins; D009070:Moxalactam